2023

1. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1

   Journal of Thrombosis and Haemostasis

2. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

   Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 4, pp. 787-799